News · BFSI
Investors at a startup summit flagged AI-led preventive healthcare, B2B fintech and SME lending as priority areas, while calling for patient capital and stronger credit strategies to build scalable Indian startups.
✦ AI SUMMARY 30-second read
- Investors identified AI-enabled preventive healthcare, drug discovery and consumer genomics as significant opportunity areas in India's health sector.
- An estimated $50 billion in annual health expenses remain uninsured, creating a financing gap that healthtech-fintech startups could address.
- Panellists argued India lacks a proven track record in patient capital, which they said constrains the emergence of multi-billion-dollar AI companies.
Why it matters: Patient capital and AI adoption across healthcare, lending and logistics could determine whether India produces globally significant startups in the next decade.
This summary was generated by AI. Editors may review and update it.
Artificial intelligence, healthcare and business-to-business fintech have been identified as the leading investment themes in India's startup ecosystem at a panel discussion held during the Shubh Lab Startup Summit by Favcy.
Investors on the panel discussed shifting venture capital priorities, stressing that the next generation of Indian startups will need patient capital, sustainable business models and broader technology adoption to succeed.
The conversation covered AI-led preventive healthcare, drug discovery, healthtech-fintech convergence, SME lending, logistics and supply chain as the sectors most likely to attract capital in the period ahead.
AI-led healthcare and preventive care
Vishal Gandhi argued that India's healthcare system must shift from a predominantly sick-care model to one centred on prevention, with AI enabling individuals to manage their own health more actively.
Gandhi pointed to drug discovery as an area where AI can deliver particular value by helping researchers identify failures more rapidly, compressing the development cycle. He also highlighted consumer genomics and microbiome analysis as fields where AI-generated insights could support personalised treatment.
On deeptech commercialisation, Gandhi raised concerns about government procurement processes that prioritise the lowest price in tenders, saying this could prevent research-intensive startups from competing effectively and securing the market access needed to scale.
Healthtech-fintech convergence
Paramdeep Singh drew attention to the financing gap in Indian healthcare, noting that close to $50 billion of health expenses are not insured, leaving patients to arrange funds before accessing treatment.
Singh said AI-enabled point-of-care financing tools could assess patients' credit requirements quickly and facilitate faster access to funds. He also linked growing interest in wellness and longevity to investment opportunity, noting that longer life expectancy needs to be matched by better health outcomes.
His remarks underlined a broader convergence between financial services technology and healthcare delivery as a distinct sector drawing investor interest.
B2B fintech, SME lending and credit strategy
Singh described B2B fintech — particularly SME lending, collections and credit management — as the segment where the most durable value will be created as the sector scales, referring to these as 'boring fintech businesses' that address real operational challenges.
He stressed that lending businesses must prioritise credit assessment and recovery over loan disbursement volume, saying that any non-banking financial company can extend loans but that the real expertise lies in getting the credit strategy right and ensuring repayment.
On consumer fintech, Singh said long-term business value would be determined more by distribution capability than by product differentiation.
Patient capital and market access for deeptech
Nitin Sethi said India has traditionally lacked a strong track record in patient investing, whether through angel networks or Category I, II and III funds, and that this gap limits the ability of startups in emerging sectors to scale over longer time horizons.
Sethi noted that multi-billion-dollar AI companies have rarely emerged from India and said this can change only when patient capital and experienced operators work together to create a multiplier effect. He also flagged B2B-to-consumer businesses, consumer technology and travel technology in Tier II and Tier III markets as areas with untapped potential.
Logistics and supply chain, particularly in addressing inefficiencies across the agricultural value chain, were highlighted by Sethi as sectors he would actively back.








